Recent Scientific Publications

Journal Articles

1. W Liu, G D Cimino, L Corash, L Lin. The Extent of Amotosalen Photoconversion during the Photochemical Treatment Process Correlates with the Level of Pathogen Inactivation. Transfusion 2010 July [epub ahead of print]
   > View abstract
   
   
2. JP Cazenave, C Waller, D Kientz, I Mendel, L Lin, M Jacquet, M Propst, W Liu, L Corash, D Sundin, L Defoin, N Messe, and JCOsselaer. An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. Transfusion. 2010 Jan. [Epub ahead of print]
   > View abstract
   
   
3. J Irsch, L Pinkoski, L Corash, L Lin. INTERCEPT plasma: comparability with conventional fresh-frozen plasma based on coagulation function – an in vitro analysis. Vox Sanguinis 2010 Jan;98(1):47-55. [Epub ahead of print]
   > View abstract
   
   
4. NA Mufti, AC Erickson, AK North, D Hanson, L Sawyer, LM Corash, L Lin. Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Biologicals. 2010 Jan;38(1):14-9. [Epub ahead of print]
   > View abstract
   
   

Conference Abstracts

XXXIst International Congress of the International Society of Blood Transfusion (ISBT)
June 26 - 1, 2010 | Berlin, Germany
[back to top]

1. Nicolas Malvaux, Paul Courrier, Michel Collart. Validation of Pooled Buffy Coat Platelet Components Suspended in a Mixture of Plasma and SSP+ Treated with INTERCEPT™ Pathogen Inactivation at Center for Transfusion Services (CTS) in Luxembourg. Vox Sanguinis 2010;99 (Suppl. 1), 253
   [Poster PDF]
   
   
2. Arzu Agildere, Sabine Reppke, Udo Schäfer et al. Implementation of 5 Buffy Coat Pooled Platelet Units Treated With INTERCEPT Blood System: Experience at the DRK Blutspendedienst in Baden-Baden. Vox Sanguinis 2010;99 (Suppl. 1), 257
   
   
3. Bettina Lizardo, Kerstin Braukmann, Inge Lüdtke et al. Implementation of 5 Buffy Coat Pooled Platelet Components Treated with the INTERCEPT Blood System™: Experience in German Red Cross Blood Donation Service Nord. Vox Sanguinis 2010;99 (Suppl. 1), 258
   [Poster PDF]
   
   
4. Maria Jessen, Igor Steinle, Maren Braun et al. Validation of Apheresis Platelet Components Treated with INTERCEPT™ Pathogen Inactivation at the Institute Schleswig German Red Cross North. Vox Sanguinis 2010;99 (Suppl. 1), 258
   
   
5. B Baumann-Baretti, G Jaster, B Brys et al. Production of Two Therapeutic Platelet Components Pathogen Inactivated with a Single INTERCEPT Dual Storage (DS) Processing Set from Double- and Triple Dose Apheresis by MCS+® and Trima 5.1 Accel®. Vox Sanguinis 2010;99 (Suppl. 1), 248
   
   
6. Mohammad R Abedi, Marie-Louise Wiiand, Ann-Charlotte Doverud et al. Apheresis Collection of Double and Triple Platelet Doses Pathogen Inactivated with INTERCEPT Blood System™: Manufacturing and Clinical Outcome. Vox Sanguinis 2010;99 (Suppl. 1), 242
   
   
7. Olivier Garraud, Fabrice Cognasse, Patricia Chavarin et al. Validation of INTERCEPT™ Pathogen Inactivation Process for Platelet Components Suspended in a Mixture of Plasma and SSP+ at a Regional Center (EFS Auvergne Loire In France). Vox Sanguinis 2010;99 (Suppl. 1), 253
   
   
8. F Ipsevich, A De Rosa, M Miceli et al. Use of Pathogen-Inactivated Apheresis and Buffy-Coat Pool Platelet Concentrates: Evaluation Program of Transfusional Quality and Efficacy. Vox Sanguinis 2010;99 (Suppl. 1), 257
   
   
9. JC Osselaer, L Defoin, C Doyen et al. INTERCEPT for Pathogen Inactivation (PI) in Platelet Concentrates (PC) Effectively Prevents Transfusion-Associated Graft-Versus-Host Disease (TA-GVHD). Vox Sanguinis 2010;99 (Suppl. 1), 428
   [Poster PDF]
   
   
10. Folke Knutson, Karin Lejskog and Helena Löf. A Feasibility Study with the TACSI™ Device Producing 2 Doses of Platelets Stored for 7 Days with the Use of One INTERCEPT™ Pathogen Inactivation Kit. Vox Sanguinis 2010;99 (Suppl. 1), 202
    
    
11. Michael Müller-Steinhardt ,Karin Janetzko. Evaluation of Apheresis Platelet Concentrates Treated with INTERCEPT™ Pathogen Inactivation. Vox Sanguinis 2010;99 (Suppl. 1), 252
    
    
12. JC Osselaer, B De Coene, MC Thonet et al. The Incidence of CNS Bleeding in Transfusion Dependent Patients Before and After Introduction of Pathogen Inactivated Platelet Components Stored for More Than 5 Days: A Nine Year Hemovigilance Survey. Vox Sanguinis 2010;99 (Suppl. 1), 433
    [Poster PDF]
    
    
13. Hervé Isola, Daniel Kientz, Marie-Louise Wiesel et al. The Use Of TACSI® System: Effect Of Automation On Routine Production Of Pooled Platelet Concentrates For Pathogen Inactivation At The EFS-Alsace. Vox Sanguinis 2010;99 (Suppl. 1), 212
    
    
14. N De Valensart, A Rapaille, R Meuter et al. Plasma from Whole Blood Treated with INTERCEPT Platelet Processing Set. Vox Sanguinis 2010;99 (Suppl. 1), 240
    [Poster PDF]
    
    
15. Sandrine Massard, Corinne Civadier, Anne Sailliol et al. Routine Production of Apheresis Plasma Pathogen Inactivated Using the INTERCEPT Blood System™: Preservation of Plasma Quality. Vox Sanguinis 2010;99 (Suppl. 1), 258
    [Poster PDF]
    
    
16. AL Pajares Herraiz, AP Rodriguez, VI Diaz et al. Modification of the INTERCEPT Processing Set for Plasma: Easier and Faster Pathogen Inactivation. Vox Sanguinis 2010;99 (Suppl. 1), 242
    
    
17. Wilfried Saldado, Françoise Le Yondre, Marie-Paule Perrault et al. Process Validation of the INTERCEPT Blood System™ for Pathogen Inactivation of Apheresis Plasma at a Regional Center (EFS-Centre Atlantique). Vox Sanguinis 2010;99 (Suppl. 1), 254
    
    
18. Olivier Garraud, Patricia Chavarin, Céline de Putter et al. Validation of the INTERCEPT Blood System™ for Pathogen Inactivation of Apheresis Plasma at a Regional Center (EFS-Auvergne Loire).
    Vox Sanguinis 2010;99 (Suppl. 1), 253
    [Poster PDF]
    
    
19. Michael Müller-Steinhardt, Karin Janetzko. Evaluation of Apheresis Plasma Treated with INTERCEPT™ Pathogen Inactivation. Vox Sanguinis 2010;99 (Suppl. 1), 251
    
    
20. Christina Lehmann, Silke Rummler, Christel Kummer et al. Pathogen Inactivation Of Single Donor Plasma. Vox Sanguinis 2010;99 (Suppl. 1), 242
    

International Plasma Fractionation Association (IPFA)
May 26 - 27, 2010 | Zagreb, Croatia
[back to top]

1. L Sawyer, S Higgs, K Tsetsarkin, D Vanlandingham, R Johnson, C Kodner, S Lam, M Koh, F Rentas, J Kinsey, D Hanson, A Sampson-Johannes. Inactivation of Transfusion-Transmitted Vector-Borne Pathogens.

12th International Haemovigilance Seminar
February 17 - 19, 2010 | Dubrovnik, Croatia
[back to top]

1. JP Cazenave, D Kientz, I Mendel, H Isola, C Waller. Hemovigilance Surveillance Of Platelet Components Prepared With Pathogen Inactivation Treatment During a Three Year Period.
   [Abstract PDF] [Poster PDF]
   
   
2. JP Cazenave, JC Osselaer, W Liu, A Elliot, W Reed, L Lin, L Corash. An Active Hemovigilance Program to Assess the Safety Outcome for 32, 480 INTERCEPT Plasma Component Transfusions.
   [Poster PDF]
   
   
3. D Domanovic, A Milojkovic, M Cukjati, J Irsch, L Lin. Hemovigilance of Transfusions with Platelet Treated with INTERCEPT Blood System Using an Active Hemovigilance Program - Data from Slovenia.
   [Abstract PDF]
   
   
4. D Kientz, I Mendel, C Waller, H Isola, JP Cazenave. Hemovigilance Surveillance Of Therapeutic Plasma Prepared With Pathogen Inactivation Treatment During a Two Year Period.
   [Poster PDF]
   
   
5. F Knutson, H Lof. HV at a University Hospital After Transfusions of Platelets Pathogen Inactivated with the INTERCEPT Technology.
   [Abstract PDF]
   
   
6. JC Osselaer, JP Cazenave, W Liu, A Elliot, W Reed, L Lin, L Corash. An Active Hemovigilance Program to Assess the Safety Outcome for 18,641 Platelet Components Tranfused in Multiple European Clinical Sites.
   [Abstract PDF]
   
   
7. JC Osselaer, B De Coene, MC Thonet, C Corlier, J Jamart, C Doyen. The Incidence of CNS Bleeding in Transfusion Dependent Patients Before and After Introduction of Pathogen Inactivated Platelet Components: A Six-year Hemovigilance Survey.
   [Poster PDF]

XXth Regional Congress, Asia, International Society Blood Transfusion
November 14 - 18, 2009 | Nagoya, Japan
[back to top]

1. JP Cazenave, A. Shimosaka, L Corash. Active Hemovigilance of Pediatric Patients Supported with Plasma Components Prepared with Photochemical Treatment (INTERCEPT™).
   [Poster PDF]
   
   
2. L Lin and L Corash. An Active Hemovigilance Program to Characterize the Safety Profile of 16,631 Platelet Components Prepared with INTERCEPT Blood System Transfused in Routine Clinical Practice.
   [Poster PDF]
   
   
3. A Shimosaka, JC Osselaer, W Liu, L Lin. Pathogen Inactivation and In Vitro Function of Platelet Components Collected in 100% Plasma Treated with INTERCEPT Blood System
   [Poster PDF]

2009 AABB Annual Meeting & TXPO
October 24 - 27, 2009 | New Orleans, USA
[back to top]

1. RE Agliastro, G DeFrancisci, M Diquattro, R Bonaccorso, M Tagliavia, M Marcatti, B Palma. Should the Use of Pathogen Inactivated Platelet Concentrates Be Extended to 7 Days? In Vitro Study on the Quality of Platelets at 3, 5 and 7 Days. Transfusion 2009; 49(suppl 1):96A
   
   
2. D P Brilhante, S Rodrigues, M Santos, L Castro. Platelet Components Treated with Pathogen Inactivation: Clinical Outcomes of the First Single Center Observational Study in Lisbon, Portugal. Transfusion 2009; 49(suppl 1):97A
   
   
3. L Defoin, L Bouchat, M Goffaux, S Vanden Bossche, P Paternostre, M Vandendaele, M van Hooydonk, JC Osselear. Transfusion Efficacy Determined by the CCI at 24 Hours Is Not Influenced by the Collected Platelet Yield with Amicus®. Transfusion 2009; 49(suppl 1):162A
   
   
4. E Girona-Llobera, TM Jimenez-Marco, M Sedeño, J Muncunill. The Impact of the Platelet Pathogen Inactivation Technology on the Platelet Inventory Management. Transfusion 2009; 49(suppl 1):266A
   
   
5. H Isola, D Kientz, F Bigey, S Somme, C Forny, J Cazenave. The Impact of Replacing Quarantine Plasma by Plasma Prepared with Pathogen Inactivation (INTERCEPT™) – Experience in EFS-Alsace. Transfusion 2009; 49(suppl 1):81A
   [Poster PDF]
   
   
6. L Sawyer, R Mababangloob, N Patel, J Kinsey, A Sampson-Johannes, D Hanson. Pathogen Inactivation Achieved with Amotosalen and UVA in Platelets Suspended in Plasma/SSP+ is Comparable to that Achieved in Platelets Suspended in Plasma/InterSol. Transfusion 2009; 49(suppl 1):95A
   [Poster PDF]

42nd Annual Congress of the German Society for Transfusion Medicine and Immunohaematology (DGTI)
September 15 - 18, 2009 | Rostock, Germany
[back to top]

1. M Deane, P Rivera, L Sawyer. INTERCEPT Platelets Treated and Stored in SSP+ Meet Council of Europe Standards for In Vitro function After 7 Days of Storage. Transfus Med Hemother 2009;36(suppl 1):1-62
   
   
2. R Henschler, M Wiesneth, H.-U Pfeiffer, M Muller, S Andresen, A Kramer, J Irsch, L Lin, L Corash, H Schrezenmeier, E Seifried. Double-Dose Platelet Concentrates Prepared from Pools of 7 or 6 Buffy Coats for Pathogen-Inactivation with the INTERCEPT System. Transfus Med Hemother 2009;36(suppl 1):1-62
   
   
3. C Lehmann, S Rummler, C Kummer, D Barz. A New Cell Free, Pathogen Inactivated Single Donor Plasma. Transfus Med Hemother 2009;36(suppl 1):1-62

6th IABS symposium on Advances in Transfusion Safety (IABS)
July 6 - 7, 2009 | Cambridge, UK
[back to top]

1. L Lin, N Mufti. Pathogen Inactivation of Red Blood Cell Concentrates (RBC) and Whole Blood (WB) Using the INTERCEPT Technology: Advances and Challenges
   [Presentation PDF]

24th Société Français de Transfusion Sanguine (SFTS)
June 22 - 25, 2009 | Strasbourg, France
[back to top]

1. S Massard, C Civadier, I Ernou, S Dhuguet, A Sanchez, C Antoinette, M Slaedts, M Joussemet. Mise en place du procede INTERCEPT sure le plasma au CTSA

Congreso Nacional de la Sociedad Espanola de Transfusion Sanguinea (SETS)
June 11 - 13, 2009 | Tarragona, Spain
[back to top]

1. E Girona-Llobera, MT Jiménez-Marco, M Sedeño, N Serra, J Muncunill. Implantación en un centro de transfusión del sistema INTERCEPT de inactivatión de patógenos de componentes plaquetarios.
   
   
2. A Pajares, L Barea, P Rodriguez, F Surribas , I Diaz, L Lopez, E Castro. Mejora en la eficiencia del sistema INTERCEPT para plasma mediante un dispositivo para mezclar 5 PFC.

14th Annual Congress of the European Hematology Association (EHA)
June 4 - 7, 2009 | Berlin, Germany
[back to top]

1. JP Cazenave, I Mendel, C Waller, JC Osselaer, M Jacquet, M Propst, L Lin, L Corash, D Kientz. Active Hemovigilance of Pediatric Patients Supported with Plasma Components Prepared with Amotosalen Plus UVA Photochemical Treatment.
   [Poster PDF]
   
   
2. P Cazenave, ML Wiesel, I Mendel, A Faradji, S Mangin, B Perricard, D Kientz. Transfusion of Platelet Components Prepared with Photochemical Pathogen Inactivation for Support of Severe Glanzmann Thrombasthenia During Surgical Procedures.
   [Poster PDF]
   
   
3. D Kientz, ML Wiesel, I Lanois, T Krummel, B Moulin, R Herbrecht, JP Cazenave. Therapeutic Plasma Exchange (TPE) for Thrombotic Thrombocytopenic Purpura (TTP) and Hemolytic Uremic Syndrome (HUS) Using Plasma Prepared with Photochemical Pathogen Inactivation: A One Year Experience in Routine Practice in a Regional Blood Center.
   [Poster PDF]
   
   
4. JC Osselaer, JP Cazenave, P Rasongles, F Knutson, L Lin and L Corash on behalf of the INTERCEPT Platelet Hemovigilance Study Group. An Active Hemovigilance Program to Characterize the Safety Profile of 16,631 Platelet Components Prepared with Photochemical Pathogen Inactivation Treatment Transfused In Routine Clinical Practice.

[back to top]